Cowen analyst Ritu Baral maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $420, as the company provided a clinical update …
In a research report issued December 7, 2014, Wedbush analyst Liana Moussatos maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT), as the company announced …
Oppenheimer analyst Akiva Felt maintained an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), as a webpage from Johns Hopkins School of Public Health states that …
In a research report issued today, Deutsche Bank analyst Alethia Young reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target …
